MA-BOARD-INTERNATIONAL
8.9.2021 16:02:19 CEST | Business Wire | Press release
Board International, the #1 Decision-Making Platform provider, today announced the appointment of Marco Limena as Chief Executive Officer. Limena will focus on expanding the rapid growth of the company while leading its next phase of development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210908005775/en/
“We are excited to welcome Marco as the new CEO of Board International. Marco is a leader who has contributed to the growth and transformation of many technology firms. Over his career, he has earned a reputation as a strategic executive, and we have tremendous confidence he will be an exceptional leader.” stated Fredrik Näslund, Partner and Head of Technology & Payments, Nordic Capital Advisors and Board Director at Board International.
“I am honored to join Board International as the company is positioned at the forefront of a critical and fast-growing market opportunity. The rapid pace of change has created an imperative for companies to reconfigure their operations and an opportunity to transform them. Board’s unique capability to unify planning and analytics and bust planning and data silos across the organization can really play a pivotal role in transforming decision-making processes in every business,” said Limena. “I am excited to join a very talented organization which, with its partner ecosystem, is fully dedicated to helping customers innovate and succeed.”
During his international career, Limena has worked in both leading technology corporations and growth-oriented B2B software businesses.
At Microsoft, Mr. Limena was Vice President of Hosting & Cloud Providers, responsible for the global B2B commercial operations of the company’s cloud software and services through the partner ecosystem. Prior to Microsoft, Marco Limena spent 14 years at HP, during which time he held several corporate roles in Palo Alto, including Vice President of HP’s telecoms solutions business.
Marco has extensive experience working with leading Private Equity firms in multiple CEO assignments in B2B software businesses, and as a Board Director in private and public companies.
“Marco is a proven technology leader and will drive the solid execution of Board’s strategy to take advantage of the many opportunities ahead, as the relevance of planning and analytics in driving enterprises’ performance continues to increase,” commented Maurizio Carli, Chairman of the company.
About Board
Board is the #1 Decision-Making Platform. Board’s solutions enable people to have a transformative impact on their business, helping them to intuitively explore and leverage their data in a flexible, all-in-one Decision-Making Platform. By unifying business Intelligence, planning, and predictive analytics, the Board platform allows companies to produce a single, accurate, and complete view of business information, gain actionable insights, and achieve full control of performance across the entire organization. Thanks to Board, more than 3,000 organizations worldwide, including H&M, Toyota, Coca-Cola, KPMG, Puma, and Sony have deployed end-to-end decision-making applications at a fraction of the time and cost associated with traditional solutions. www.board.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005775/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom